PURPOSE: The aim of this study was to assess the effects of topical application of a 10% (w/w) freeze-dried black raspberry (FBR) gel on oral intraepithelial neoplasia (IEN) variables that included histologic diagnoses and loss of heterozygosity (LOH) indices. Microsatellite instability and/or LOH at tumor suppressor gene-associated chromosomal loci have been associated with a higher risk for oral IEN progression to oral squamous cell carcinoma. Previously, our laboratories have shown that FBRs are well tolerated and possess potent antioxidant, apoptotic, and differentiation-inducing properties. EXPERIMENTAL DESIGN: Each participant with IEN served as their own internal control. Before treatment, all lesions were photographed, and lesional tissue was hemisected to obtain a pretreatment diagnosis and baseline biochemical and molecular variables. Gel dosing (0.5 g applied four times daily for 6 weeks) was initiated 1 week after the initial biopsy. Genomic DNA was isolated from laser-captured basilar and suprabasilar surface epithelial cells followed by PCR amplification using primer sets that targeted known and presumed tumor suppressor gene loci associated with INK4a/ARF, p53, and FHIT. Allelic imbalance was determined by sequence analysis using normal participant tissues to establish microsatellite marker peak patterns and allele sizes. RESULTS: Confirming earlier phase I data, none of the 27 participants developed FBR gel-associated toxicities. Furthermore, our results show histologic regression in a subset of patients as well as statistically significant reduction in LOH at tumor suppressor gene-associated loci. CONCLUSIONS: These preliminary data suggest that further evaluation of berry gels for oral IEN chemoprevention is warranted.
PURPOSE: The aim of this study was to assess the effects of topical application of a 10% (w/w) freeze-dried black raspberry (FBR) gel on oral intraepithelial neoplasia (IEN) variables that included histologic diagnoses and loss of heterozygosity (LOH) indices. Microsatellite instability and/or LOH at tumor suppressor gene-associated chromosomal loci have been associated with a higher risk for oral IEN progression to oral squamous cell carcinoma. Previously, our laboratories have shown that FBRs are well tolerated and possess potent antioxidant, apoptotic, and differentiation-inducing properties. EXPERIMENTAL DESIGN: Each participant with IEN served as their own internal control. Before treatment, all lesions were photographed, and lesional tissue was hemisected to obtain a pretreatment diagnosis and baseline biochemical and molecular variables. Gel dosing (0.5 g applied four times daily for 6 weeks) was initiated 1 week after the initial biopsy. Genomic DNA was isolated from laser-captured basilar and suprabasilar surface epithelial cells followed by PCR amplification using primer sets that targeted known and presumed tumor suppressor gene loci associated with INK4a/ARF, p53, and FHIT. Allelic imbalance was determined by sequence analysis using normal participant tissues to establish microsatellite marker peak patterns and allele sizes. RESULTS: Confirming earlier phase I data, none of the 27 participants developed FBR gel-associated toxicities. Furthermore, our results show histologic regression in a subset of patients as well as statistically significant reduction in LOH at tumor suppressor gene-associated loci. CONCLUSIONS: These preliminary data suggest that further evaluation of berry gels for oral IEN chemoprevention is warranted.
Authors: Chuanshu Huang; Jingxia Li; Lun Song; Dongyun Zhang; Qiangsong Tong; Min Ding; Linda Bowman; Robeena Aziz; Gary D Stoner Journal: Cancer Res Date: 2006-01-01 Impact factor: 12.701
Authors: Gary D Stoner; Christine Sardo; Glen Apseloff; Dan Mullet; Wayne Wargo; Vickie Pound; Alpana Singh; James Sanders; Robeena Aziz; Bruce Casto; XiaoLi Sun Journal: J Clin Pharmacol Date: 2005-10 Impact factor: 3.126
Authors: Laura A Kresty; Wendy L Frankel; Cynthia D Hammond; Maureen E Baird; Jennifer M Mele; Gary D Stoner; John J Fromkes Journal: Nutr Cancer Date: 2006 Impact factor: 2.900
Authors: Kapila A Rodrigo; Yeshwant Rawal; Robert J Renner; Steven J Schwartz; Qingguo Tian; Peter E Larsen; Susan R Mallery Journal: Nutr Cancer Date: 2006 Impact factor: 2.900
Authors: Scott M Lippman; J Jack Lee; Jack W Martin; Adel K El-Naggar; Xiaochun Xu; Dong M Shin; Margaret Thomas; Li Mao; Herbert A Fritsche; Xian Zhou; Vassiliki Papadimitrakopoulou; Fadlo R Khuri; Hai Tran; Gary L Clayman; Walter N Hittelman; Waun Ki Hong; Reuben Lotan Journal: Clin Cancer Res Date: 2006-05-15 Impact factor: 12.531
Authors: Ahmedin Jemal; Rebecca Siegel; Elizabeth Ward; Taylor Murray; Jiaquan Xu; Michael J Thun Journal: CA Cancer J Clin Date: 2007 Jan-Feb Impact factor: 508.702
Authors: Xiao Wu; Kashappa-Goud H Desai; Susan R Mallery; Andrew S Holpuch; Maynard P Phelps; Steven P Schwendeman Journal: Mol Pharm Date: 2012-03-06 Impact factor: 4.939
Authors: Blake M Warner; Bruce C Casto; Thomas J Knobloch; Brent T Accurso; Christopher M Weghorst Journal: Oral Surg Oral Med Oral Pathol Oral Radiol Date: 2014-09-16
Authors: Andrew S Holpuch; Maynard P Phelps; Kashappa-Goud H Desai; Wei Chen; George M Koutras; Byungdo B Han; Blake M Warner; Ping Pei; Garrett A Seghi; Meng Tong; Michael B Border; Henry W Fields; Gary D Stoner; Peter E Larsen; Zhongfa Liu; Steven P Schwendeman; Susan R Mallery Journal: Carcinogenesis Date: 2012-03-15 Impact factor: 4.944
Authors: Brent T Accurso; Blake M Warner; Thomas J Knobloch; Christopher M Weghorst; Brian S Shumway; Carl M Allen; John R Kalmar Journal: Oral Surg Oral Med Oral Pathol Oral Radiol Endod Date: 2011-07-20
Authors: Andrew S Holpuch; Garrett J Hummel; Meng Tong; Garrett A Seghi; Ping Pei; Ping Ma; Russell J Mumper; Susan R Mallery Journal: Pharm Res Date: 2010-03-31 Impact factor: 4.200